PPT-Switch to E/C/F/TAF + DRV
Study GSUS2920119 ECFTAF DRV 800 mg QD N 89 N 46 Baseline regimen Design Randomisation 2 1 Openlabel Objective Primary Endpoint proportion with treatment success
Download Presentation
"Switch to E/C/F/TAF + DRV" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement. Download
Presentation Transcript
Transcript not available.